IPO - Aurion Biotech, Inc.

Form Type: DRS/A

Filing Date: 2024-12-10

Corporate Action: Ipo

Type: New

Accession Number: 000095012324012206

Filing Summary: Aurion Biotech, Inc. is conducting an initial public offering (IPO) for its common stock, having confidentially submitted its registration statement to the SEC. The company's lead product, AURN001, is a regenerative therapy targeting corneal endothelial diseases, with a launch of its first-generation therapy Vyznova in Japan. AURN001 aims to provide enhanced treatment options for patients suffering from significant vision loss. The company estimates a total addressable market of nearly $8 billion annually in the U.S. alone. Aurion is classified as an emerging growth company with a commitment to develop innovative therapies to restore vision.

Form Type: DRS

Filing Date: 2024-10-21

Corporate Action: Ipo

Type: New

Accession Number: 000095012324009779

Filing Summary: Aurion Biotech, Inc. has confidentially submitted a draft registration statement for an initial public offering (IPO) of its common stock to the Securities and Exchange Commission (SEC). The registration statement is designated under the Securities Act of 1933 as Form S-1. The company is focused on developing regenerative therapies for corneal endothelial diseases, highlighting the potential of its lead product candidate, AURN001, which has shown clinical efficacy in improving corneal health in patients experiencing vision loss. They have received Breakthrough Therapy Designation and Regenerative Medicines Advanced Therapy Designation from the FDA, facilitating their path to regulatory approval. Aurion aims to address significant unmet needs in treating corneal blindness globally, which according to estimates affects a substantial portion of the population aged 30 and older, presenting a large market opportunity for effective treatments.